Basic Science & Pathogenesis Providing Quality HIV Care HIV Treatment Strategies FDA-Approved HIV Medications Adverse Events & Comorbidities Care & Services Outside the U.S.

Mental Health Discrimination & Law Meeting the Costs of Care Case Management & Social Work Policy & Advocacy Care & Services Outside the U.S.

HIV Transmission & Testing

Epidemiology Education & Risk Management Prevention Methods HIV Testing

Research & Conferences

This Week in HIV Research IAS 2019: What to Expect in HIV Science CROI 2019 All Conference Coverage Newsroom

All Categories Visit TheBody (Our HIV Community Resource)

SUBSCRIBE TO OUR NEWSLETTER

About Contact Write For Us

https://www.thebodypro.com/author/bristol-myers-squibb-company-and-gilead-sciences

Bristol-Myers Squibb Company and Gilead Sciences, Inc.

Conditions Covered: Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada), Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (Atripla), Efavirenz (Sustiva, Stocrin),

Latest by Bristol-Myers Squibb Company and Gilead Sciences, Inc.

News

Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce

New York, NY and Foster City, CA -- Bristol-Myers Squibb Company (NYSE: BMY) and Gilead Sciences, Inc. (Nasdaq: GILD) today announced they have obtained data supporting bioequivalence of a new formulation of the fixed-dose combination of Bristol-Myer...

By Bristol-Myers Squibb Company and Gilead Sciences, Inc.

About Contact Write For Us

SUBSCRIBE TO OUR NEWSLETTER

Remedy Health Media Sites Privacy Policy Cookie Declaration Terms of Use Security Policy Advertising Policy Advertise With Us